Table 4.
ORs (95% CI) for PASI 75 Response 6 Months after Biologic Initiation in 2018 by US Geographic Region in the Corrona Psoriasis Registry, Stratified by Biologic Class
| Regions | TNFi |
IL-17i |
IL-12/23i + IL-23i |
|||
|---|---|---|---|---|---|---|
| % Responders | Adjusted OR1 | % Responders | Adjusted OR1 | % Responders | Adjusted OR1 | |
| Northeast | 47 (9/19) | Ref | 58 (45/77) | Ref | 64 (74/116) | Ref |
| Pacific | 63 (15/24) | 0.73 (0.16–3.23) | 56 (28/50) | 0.66 (0.29–1.52) | 38 (11/29) | 0.26 (0.10–0.65)2 |
| Mountain/West North Central | 59 (13/22) | 1.31 (0.34–5.06) | 65 (28/43) | 1.46 (0.65–3.27) | 43 (12/28) | 0.46 (0.19–1.11) |
| West South Central | 33 (2/6) | 0.49 (0.06–3.95) | 53 (10/19) | 0.94 (0.32–2.74) | 27 (6/22) | 0.24 (0.08–0.67)2 |
| East North Central | 44 (4/9) | 0.68 (0.11–4.19) | 63 (15/24) | 1.24 (0.47–3.28) | 40 (8/20) | 0.39 (0.14–1.06) |
| East South Central | 29 (8/28) | 0.44 (0.11–1.72) | 48 (31/65) | 0.63 (0.31–1.27) | 35 (8/23) | 0.30 (0.11–0.80)3 |
| South Atlantic | 38 (6/16) | 0.50 (0.12–2.13) | 52 (24/46) | 0.72 (0.34–1.54) | 56 (20/36) | 0.69 (0.31–1.52) |
Abbreviations: CI, confidence interval; IL-12/23i, IL-12‒IL-23 inhibitor; IL-17i, IL-17 inhibitor; IL-23i, IL-23 inhibitor; PASI 75, 75% improvement in PASI; TNFi, TNF inhibitor; Ref, reference; US, United States.
1
Adjusted for age, sex, race, BMI, and baseline BSA.
2
Significant at P < 0.01.
3
Significant at P < 0.05.